Biogen looks to expand neuro pipeline via C4, Skyhawk deals

A pair of deals announced Jan. 4 leaves Biogen Inc. (NASDAQ:BIIB) poised to expand the druggable space of its neurology pipeline. Biogen entered R&D partnerships with targeted protein degradation company C4 Therapeutics Inc. (Cambridge, Mass.) and spliceosome company Skyhawk Therapeutics Inc. (Waltham, Mass.).

Skyhawk uses its SkySTAR platform to develop small molecules capable of

Read the full 531 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE